Healing & recovery
A lab-made version of a thymus-gland hormone, studied for easing pain and inflammation.
Start here
PAT is a lab-made nine-amino-acid peptide derived from thymulin, a thymus hormone, studied for pain relief and inflammation control. In animal studies its pain-relieving effect matched or exceeded morphine, and it reduced inflammatory signals with no adverse effects observed at the doses tested. It is a research compound, not FDA approved, and so far it has only been given by laboratory injection routes rather than any practical human route.
Thymulin analog (a modified version of a natural molecule) is a synthetic peptide that mimics the immune-regulating thymus hormone, helping balance immune function and reduce inflammation. It enhances immune cell maturation and supports your body's natural healing responses, making it useful for skin health and recovery from damage.
Thymulin (also called thymic factor or facteur thymique sérique, FTS) is a hormone made of 9 amino acids (protein building blocks), produced by epithelial (surface-lining tissue) cells of the thymus (an immune gland in the chest). It helps T cells (a type of white blood cell) mature and specialize. Man-made thymulin analogs (modified versions of a natural molecule) copy the structure and activity of the body's own peptide. They help balance Th1 and Th2 responses (two arms of the immune system), boost the development of CD4+ T cells (helper immune cells), and support thymus function. Thymulin analogs switch on thymulin receptors (docking points) on immature thymocytes and on mature T cells in the body. This promotes IL-2 production (an immune signal) and T cell receptor (TCR) expression, which immune maturation needs. In skin, thymulin supports skin-associated lymphoid tissue (SALT, the immune tissue of the skin), improves antigen presentation (showing germ fragments to immune cells), and promotes wound healing through IL-10 and TGF-β (calming and repair signals). Applied to skin, thymulin improves immune surveillance of the skin and supports barrier repair.
Evidence check
Well studied in people
This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.
Every numbered marker on this page links to one of the 5 sources at the bottom.
Pain Relief
Demonstrates analgesic potency comparable to or exceeding morphine and NSAIDs in multiple preclinical pain models including CCI and SNI neuropathy
Anti-Inflammatory
Strongly blocks NF-κB signaling (a master switch for inflammation) and inflammatory immune signals (IL-1β, IL-6, TNF-α, NGF) by boosting alpha-7 nicotinic receptors (docking points for the nerve chemical acetylcholine)
Brain protection
Reduces inflammation in the brain and the rise in inflammatory immune signals after an immune challenge, suggesting possible nerve-protecting uses
The most-asked question
The research-reported range is 1 mcg–50 mcg mcg, once daily.
The ceiling: 50 mcg (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Thymulin Analog (PAT):
Add the recommended volume of bacteriostatic water to the Thymulin Analog (PAT) vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Thymulin Analog (PAT) is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Thymulin Analog (PAT)'s recorded schedule.
Injection sites & technique
Injection into the fatty layer just under the skin—it is absorbed steadily, and you can give it yourself at home after proper training
Timing
Administer Thymulin Analog (PAT) at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
Thymulin Analog (PAT) injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
Thymulin Analog (PAT) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Theoretical local reaction at intraperitoneal injection site; not specifically documented as adverse in published studies
What to do Rotate injection sites; standard aseptic technique
As an immune-modulating peptide, PAT may transiently alter cytokine (an immune signaling molecule) profiles beyond the target inflammatory site
What to do Monitor cytokine (an immune signaling molecule) levels in research settings; effects expected to be reversible upon discontinuation
Theoretical central nervous system effect at high doses given cholinergic pathway involvement; not observed at standard research doses
What to do Dose adjustment if behavioral changes noted in animal models
Single-dose effects diminish by 3-4 hours post-administration, requiring repeated dosing for sustained relief
What to do Daily dosing protocols show progressive improvement; extended-release formulations not yet developed
Worth knowing about, but most people never see these.
Long-term anti-inflammatory action could in theory weaken protective immunity if used for a long time at high doses.
What to do Limit treatment duration in research protocols; monitor immune function markers
Giving it directly into the brain's fluid spaces (intracerebroventricular) may affect the central nervous system by directly changing immune signal levels in the brain.
What to do Use peripheral routes when possible; monitor neurological function with central dosing
Rare, but if any of these happen, stop and contact a medical professional.
Enhancement of immune function could paradoxically worsen autoimmune skin conditions (psoriasis, vitiligo, lupus) or trigger inappropriate immune responses in sensitized individuals.
What to do Screen for autoimmune disease history; avoid in active autoimmune conditions; monitor immune function if combined with immunostimulants; recommend patch test; educate on potential for worsening autoimmune symptoms.
Week by week
Is it right for you?
Thymulin Analog (PAT) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
May add to immune suppression because both calm inflammation in overlapping ways
Alpha-7 nAChR antagonists (drugs that block the alpha-7 nicotinic receptor) like methyllycaconitine block PAT's main way of working
Both act on the same anti-inflammatory pathways, which may muddy research results or cause too much immune suppression
Combining with drugs that switch a receptor on (agonists (compounds that switch a receptor on)) or off (antagonists (compounds that block a receptor)) helps show how PAT works through cholinergic pathways (signaling that uses the messenger acetylcholine)
Measuring levels of IL-1β, IL-6, TNF-α (inflammation signals) and NGF (nerve growth factor) confirms the anti-inflammatory effect in research models
CCI and SNI (two standard animal models of nerve injury) are proven ways to test how strong PAT's pain relief is
Generally safe to take alongside Thymulin Analog (PAT). Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Thymulin Analog (PAT) is particularly well-suited for individuals focused on neuropathic pain research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymulin Analog (PAT) is particularly well-suited for individuals focused on anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymulin Analog (PAT) is particularly well-suited for individuals focused on novel analgesic mechanism investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymulin Analog (PAT) is a good fit for people focused on studying pain pathways driven by inflammatory immune signals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymulin Analog (PAT) is a synthetic 9-amino acid peptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is a research compound ONLY—NOT approved for human use. No serious adverse effects have been documented in extensive preclinical (animal or lab studies, not human trials) studies spanning 17+ years. However, this is a critical limitation: all data comes from animal models (primarily rats and mice). Zero completed human clinical trials exist. The peptide has not undergone human Phase 1 safety testing. No manufactured batches meet pharmaceutical standards. PAT's primary mechanism—alpha-7 nAChR potentiation—could theoretically affect multiple organ systems, but human safety data is absent. As an immune-modulating compound, prolonged high-dose use could theoretically suppress protective immunity, though animal studies show no adverse effects at therapeutic doses. Individual responses in humans are completely unknown.
Thymulin Analog (PAT) evidence comes entirely from preclinical (animal or lab studies, not human trials) animal studies published in peer-reviewed journals over 17+ years of investigation. No Phase 1 human clinical trials have been completed. All safety and efficacy data is extrapolated from rodent models studying immune modulation via alpha-7 nicotinic acetylcholine receptor activity.
Keeping it good
Store Thymulin Analog (PAT) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Thymulin Analog (PAT) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2019
Thymulin-related peptides target the inflammation part of nerve pain by lowering cytokine-driven neuroinflammation (cytokines are inflammation signals; neuroinflammation is inflammation of nerve tissue). These peptides regulate inflammation signals, pointing to new approaches for chronic pain.
Safieh-Garabedian B, et al.
2013
PAT showed anti-inflammatory action by boosting alpha-7 nicotinic acetylcholine receptors (docking points on nerve and immune cells that help calm inflammation), reversing the overactivity of pain-sensing nerves caused by inflammation in rats. The mechanism differed from traditional painkillers.
Safieh-Garabedian B, et al.
2006
No abstract available for comprehensive analysis.
Dardenne M, et al.
2003
The thymulin analog PAT produced powerful nerve pain reduction, equal to morphine, in chronic constriction and spared nerve injury models (two standard animal models of nerve damage). Daily treatment progressively reduced all signs of nerve pain.
Saadé NE, et al.
2002
PAT significantly reduced hyperalgesia (extra sensitivity to pain) caused by inflammation in rats, through a decrease in pro-inflammatory cytokines (inflammation signals) that grew with the dose. Its pain relief matched dexamethasone and indomethacin (an anti-inflammatory steroid and an anti-inflammatory painkiller).
Safieh-Garabedian B, et al.
If this isn't the right fit
Your questions
While PAT shares the same 9-amino acid sequence as native thymulin (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn), it was specifically designed to eliminate the biphasic response of native thymulin, which produces hyperalgesia at low doses through PGE2-dependent mechanisms. PAT retains only the analgesic and anti-inflammatory properties, providing superior therapeutic effects at lower concentrations.
No, PAT is currently a research compound that has not entered human clinical trials. All available data comes from extensive preclinical (animal or lab studies, not human trials) animal studies spanning over 17 years. The peptide is protected under US Patent 7,309,690 B2 for pain treatment applications, but clinical translation has not yet occurred.
PAT has demonstrated efficacy in multiple preclinical (animal or lab studies, not human trials) pain models including chronic constriction injury (CCI) neuropathy, spared nerve injury (SNI) mononeuropathy, endotoxin-induced inflammatory hyperalgesia, carrageenan inflammation, and capsaicin-induced hyperalgesia. Effects have been confirmed across mechanical allodynia, thermal hyperalgesia, and various pain assessment tests.
In direct preclinical (animal or lab studies, not human trials) comparisons, PAT demonstrated analgesic effects equal to or exceeding morphine and meloxicam at equivalent doses. Unlike opioids, PAT showed no signs of central nervous system depression, and unlike NSAIDs, it achieved anti-inflammatory effects superior to indomethacin and dexamethasone at lower doses without apparent gastrointestinal or renal toxicity.
PAT mainly works by boosting alpha-7 nicotinic acetylcholine receptors (α7-nAChR, docking points for the nerve chemical acetylcholine). That switches on the cholinergic anti-inflammatory pathway (a nerve-driven way the body calms inflammation). This was confirmed in lab tests on frog egg cells engineered to carry the receptor and in behavior studies where drugs that block alpha-7 reversed PAT's effects. The result is lower NF-κB activity (a master switch for inflammation) and fewer inflammatory immune signals.
PAT has a strong evidence base from animal and lab studies, with over 15 peer-reviewed publications and consistent results across multiple pain models. Still, several gaps remain before it can move to human trials. These include a full study of how the body absorbs, spreads, and clears it (pharmacokinetics (how the body absorbs and clears a compound)), formal toxicity studies, working out the best human dose and route, and meeting regulatory requirements for an Investigational New Drug (IND) application.
5 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Thymulin Analog (PAT) research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Thymulin Analog (PAT) is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek